Serge Verreault, Crescita Therapeutics: Advancing Pliaglis in Europe

TL;DR

Serge Fournier discusses the conference, Cristina Therapeutics' licensing agreement with Cantabria, focus on dermatology, and the differences between the US and Canadian healthcare markets.

Transcript

I'm Jocelyn as play with the investing news network at this year's bloom Burton health care investor conference I spoke with Serge 4ro CEO of Cristina therapeutics I asked him what his thoughts were on the conference so far and what his company is up to this year take a look at our video can you tell me so far how the conference has been treating y... Read More

Key Insights

• ❓ The Bloomberg Burton Healthcare Investor Conference is expected to benefit Cristina Therapeutics.
• 🏤 The licensing agreement with Cantabria expands the sales of Plegridy in four European countries.
• 🚚 Cristina Therapeutics focuses on dermatology and leverages their patented delivery system technologies.
• 🙈 The company sees potential in partnering for the commercialization of their products in other countries.
• 🖐️ Dermatology plays a significant role in Cristina Therapeutics' product portfolio and expansion plans.
• 🏁 The milestone of FDA approval for Plegridy has made it more accessible to patients.
• ❓ The US and Canadian healthcare markets have differences in market size and reimbursement systems.

Questions & Answers

Q: How has the conference been so far for Cristina Therapeutics?

Fournier believes the conference will be valuable for the company and they have received positive interest from industry professionals.

Q: Can you explain the licensing agreement with Cantabria for Plegridy?

Cristina Therapeutics reacquired the rights to Plegridy for 26 countries and decided to license it out immediately. Cantabria was chosen as a partner due to its strong presence in dermatology in Italy, Portugal, France, and Spain.

Q: Why is Cristina Therapeutics interested in dermatology?

The company has two patented delivery system technologies that can enhance the penetration of active ingredients in the skin. They see dermatology as a growth opportunity and have partnerships for psoriasis and other dermatological indications.

Q: How significant was the milestone of getting FDA approval for Plegridy?

The removal of FDA restrictions allowing patients to use the product at home instead of a medical clinic has opened up the market and made it easier for physicians to prescribe the product.

Q: What are the differences between the US and Canadian healthcare markets?

Canada has a smaller market size compared to the US, so it is more feasible for pharmaceutical companies to focus on the US market. Reimbursement and healthcare practitioner involvement are important in both markets, but a company needs a presence in Canada to access that market.

Summary & Key Takeaways

• Serge Fournier is positive about the Bloomberg Burton Healthcare Investor Conference and expects it to be beneficial for Cristina Therapeutics.

• Cristina Therapeutics recently announced a licensing agreement with Cantabria to sell their product Plegridy in Italy, Portugal, France, and Spain.

• The company is focused on dermatology and is looking to maximize their patented delivery system technology and non-prescription portfolio.